Phase 1 N=41 Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
Psoriasis
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 6; 5; 5; 6 subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
Carney Complex · Chondrosarcoma · Gastrointestinal Stromal Tumor
Primary: Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1 — 0 participants
Phase 3 N=62 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Percentage of Participants With a Durable Platelet Response — 10.0; 52.4 percentage of participants — p=0.0018
Phase 3 N=111 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer
Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 · Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Primary: Two Year Event-free Survival (EFS) — 0.87 Estimated probability
N/A N=28 iTotal Pilot Study of ConforMIS Custom Total Knee Implant
Knee Arthroplasty, Total
Primary: Distance Measured During 6-minute Walk Test — 1060 feet
Phase 2 N=26 Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002
Phase 2 N=36 Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma
Hodgkin's Disease · Lymphoma
Primary: Determine the Overall Response Rate (RR) to Bendamustine HCL in Patients With Relapsed and Primary Refractory HL. — 56 percentage of evaluable participants
Phase 3 N=544 A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Rheumatoid Arthritis
Primary: American College of Rheumatology 20% Response Criteria (ACR20) — 72.4; 72.2 percentage of participants
Phase 2 N=16 Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
Mouth Neoplasms · Head and Neck Neoplasms · Tongue Neoplasms
Primary: Percent (%) Change in Levels of pS6, pAKt473, and Ki-67 — -60.60; -67.24; -31.48; 100.00 percentage of change from baseline
Phase 1 N=78 Phase 1, Febuxostat XR Relative Bioavailability Study
Healthy Volunteers
Primary: Mean Cmax: Maximum Observed Plasma Concentration for Febuxostat — 2027.1184; 1442.2267; 1730.2468; 1809.3158 ng/mL
Phase 2 N=13 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
Sarcoma
Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin
N/A N=228 Effects of Heart Imaging Radiation on DNA Double-Stranded Breaks in Blood Lymphocytes and Hair Follicle Cells
Coronary Artery Disease · Chest Pain
Primary: Number of Excess Double-strand DNA Break Foci Per Cell in Peripheral Blood Samples Post-imaging — 0.183; 0.159 gamma-H2AX foci in blood lymphocytes — p=<0.05
Phase 2 N=87 Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer
Adenomatous Polyp · Colorectal Carcinoma
Primary: Difference (After Treatment Minus Before Treatment) of EGFR Expression — 0.17; -0.40; 0.21 ng/ml
Phase 3 N=159 Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)
Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12) — 93.5; 91.8 Percentage of participants
Phase 2 N=34 Antineoplaston Therapy in Treating Children With Brain Tumors
Childhood Brain Tumors
Primary: Number of Participants With Objective Response — 1; 5; 6; 18 Participants